SunTech Medical, Valencell team-up to improve blood pressure measurements

The multi-year agreement will allow the companies to work together to develop customized solutions and products for other medical device OEMs.

SunTech Medical

SunTech Medical, which is the leading provider of clinical-grade blood pressure measurement technologies and devices, is teaming up with biometric sensors maker Valencell to jointly develop new blood pressure measurement solutions that will enhance patient safety.

The goal is to combine the accuracy of SunTech’s Advantage cuff-based blood pressure technology, and its superior TMT (Transport Motion Tolerance) capabilities, with continuous BP estimation from Valencell’s optical PPG (photoplethysmography) technology, in order to provide a new and better BP measurement solution for higher acuity market segments like hemodialysis, emergency medicine, OR and ICU, ambulatory BP studies and cardiac rehabilitation, and sleep.

This multi-year agreement will allow the companies to work together to develop customized solutions and products for other medical device OEMs, as well as allowing SunTech to incorporate Valencell technology in its finished, branded products.‚Äč

“The combination of multiple motion-tolerant technologies and measurement modalities from SunTech and Valencell will enable comfortable, continuous, clinical-grade BP monitoring for many applications,” said Paul Matsumura, SunTech’s Senior Director of Research and Technology about how the technologies could work in concert.

“SunTech and Valencell are each the best in their field of motion tolerant blood pressure and PPG technology, respectively. Both together is a winning combination in the clinical space,” added Julian Mullaney, SunTech’s Vice President of R&D about the deal.

Dr. Steven LeBeouf, Valencell’s President and Co-Founder, also had two cents to add: “Our two companies have identified critical medical use cases that can only be effectively addressed by combining Valencell’s deep-PPG technology with SunTech’s motion-tolerant blood pressure technology.”

The collaboration agreement was signed in conjunction with an investment in Valencell by SunTech Medical’s parent corporation, Halma plc.